Summary Treatment with benralizumab significantly reduced nasal TSLP in patients with severe asthma. Nasal TSLP shows potential as a pharmacodynamic biomarker, pending validation in larger, randomized studies.
No takes yet. Share an insight, caveat, or question.
Marriott et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: